Cargando…
A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis
PURPOSE: FASTR was designed to provide a compact treatment course for high-risk prostate cancer patients but was discontinued because of excess toxicity. We present the results of FASTR-2, which used a lower dose to the prostate (35 Gy vs 40 Gy), smaller posterior PTV margin (4 mm vs 5 mm) and omitt...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817718/ https://www.ncbi.nlm.nih.gov/pubmed/31681864 http://dx.doi.org/10.1016/j.adro.2019.07.007 |
_version_ | 1783463483165114368 |
---|---|
author | Callan, Laura Bauman, Glenn Chen, Jeff Lock, Michael Sexton, Tracy D'Souza, David Rodrigues, George |
author_facet | Callan, Laura Bauman, Glenn Chen, Jeff Lock, Michael Sexton, Tracy D'Souza, David Rodrigues, George |
author_sort | Callan, Laura |
collection | PubMed |
description | PURPOSE: FASTR was designed to provide a compact treatment course for high-risk prostate cancer patients but was discontinued because of excess toxicity. We present the results of FASTR-2, which used a lower dose to the prostate (35 Gy vs 40 Gy), smaller posterior PTV margin (4 mm vs 5 mm) and omitted nodal radiation to lower the volumes of rectum receiving high and intermediate doses compared with FASTR. Gastrointestinal (GI) and genitourinary (GU) toxicities at baseline, 6 weeks, 6 months, and 1 year and biochemical control rates are presented. METHODS AND MATERIALS: Eligibility included high-risk prostate cancer (cT3/4, prostate-specific antigen >20 or Gleason Score ≥8), age ≥70 or refused standard treatment, and no evidence of metastatic disease. Patients received 18 months of androgen deprivation therapy starting 2 months before radiation. Clinical target volume was defined as prostate plus proximal 1-cm seminal vesicles. PTV was a nonuniform expansion around clinical target volume (4 mm posteriorly, 5 mm in all other directions). Volumetric arc therapy was used for treatment delivery (35 Gy delivered in 5 weekly fractions of 7 Gy each), and cone beam computed tomography with soft tissue matching (no fiducial placement) was used for daily image guidance. Toxicity was assessed at 6 weeks, 6 months, and 1 year according to Common Toxicity Criteria. RESULTS: In the study, 30 patients were enrolled in FASTR-2 between 2015 and 2017. Two patients were withdrawn owing to ineligibility after enrollment. One patient (3.7%) reported grade 2 GI toxicity at 6 weeks. There was no reported grade ≥2 GI toxicity at 6 months or 1 year. There were no reported episodes of rectal bleeding. Four patients (14.8%), 5 patients (17.9%), and 5 patients (21.7%) reported grade 2 GU toxicity at 6 weeks, 6 months, and 1 year, respectively. There were no reported cases of grade ≥3 GU toxicity. The most common toxicities were nocturia and urinary frequency or urgency. CONCLUSIONS: FASTR-2 was more tolerable than FASTR, with no grade ≥3 toxicities reported, in keeping with expectations based on our previous FASTR analysis. Long-term follow-up is necessary to ensure disease control and toxicity outcomes are comparable to conventional high-risk treatment paradigms. |
format | Online Article Text |
id | pubmed-6817718 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-68177182019-11-01 A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis Callan, Laura Bauman, Glenn Chen, Jeff Lock, Michael Sexton, Tracy D'Souza, David Rodrigues, George Adv Radiat Oncol Genitourinary Cancer PURPOSE: FASTR was designed to provide a compact treatment course for high-risk prostate cancer patients but was discontinued because of excess toxicity. We present the results of FASTR-2, which used a lower dose to the prostate (35 Gy vs 40 Gy), smaller posterior PTV margin (4 mm vs 5 mm) and omitted nodal radiation to lower the volumes of rectum receiving high and intermediate doses compared with FASTR. Gastrointestinal (GI) and genitourinary (GU) toxicities at baseline, 6 weeks, 6 months, and 1 year and biochemical control rates are presented. METHODS AND MATERIALS: Eligibility included high-risk prostate cancer (cT3/4, prostate-specific antigen >20 or Gleason Score ≥8), age ≥70 or refused standard treatment, and no evidence of metastatic disease. Patients received 18 months of androgen deprivation therapy starting 2 months before radiation. Clinical target volume was defined as prostate plus proximal 1-cm seminal vesicles. PTV was a nonuniform expansion around clinical target volume (4 mm posteriorly, 5 mm in all other directions). Volumetric arc therapy was used for treatment delivery (35 Gy delivered in 5 weekly fractions of 7 Gy each), and cone beam computed tomography with soft tissue matching (no fiducial placement) was used for daily image guidance. Toxicity was assessed at 6 weeks, 6 months, and 1 year according to Common Toxicity Criteria. RESULTS: In the study, 30 patients were enrolled in FASTR-2 between 2015 and 2017. Two patients were withdrawn owing to ineligibility after enrollment. One patient (3.7%) reported grade 2 GI toxicity at 6 weeks. There was no reported grade ≥2 GI toxicity at 6 months or 1 year. There were no reported episodes of rectal bleeding. Four patients (14.8%), 5 patients (17.9%), and 5 patients (21.7%) reported grade 2 GU toxicity at 6 weeks, 6 months, and 1 year, respectively. There were no reported cases of grade ≥3 GU toxicity. The most common toxicities were nocturia and urinary frequency or urgency. CONCLUSIONS: FASTR-2 was more tolerable than FASTR, with no grade ≥3 toxicities reported, in keeping with expectations based on our previous FASTR analysis. Long-term follow-up is necessary to ensure disease control and toxicity outcomes are comparable to conventional high-risk treatment paradigms. Elsevier 2019-07-16 /pmc/articles/PMC6817718/ /pubmed/31681864 http://dx.doi.org/10.1016/j.adro.2019.07.007 Text en © 2019 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Genitourinary Cancer Callan, Laura Bauman, Glenn Chen, Jeff Lock, Michael Sexton, Tracy D'Souza, David Rodrigues, George A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis |
title | A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis |
title_full | A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis |
title_fullStr | A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis |
title_full_unstemmed | A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis |
title_short | A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis |
title_sort | phase i/ii trial of fairly brief androgen suppression and stereotactic radiation therapy for high-risk prostate cancer (fastr-2): preliminary results and toxicity analysis |
topic | Genitourinary Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817718/ https://www.ncbi.nlm.nih.gov/pubmed/31681864 http://dx.doi.org/10.1016/j.adro.2019.07.007 |
work_keys_str_mv | AT callanlaura aphaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT baumanglenn aphaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT chenjeff aphaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT lockmichael aphaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT sextontracy aphaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT dsouzadavid aphaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT rodriguesgeorge aphaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT callanlaura phaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT baumanglenn phaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT chenjeff phaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT lockmichael phaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT sextontracy phaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT dsouzadavid phaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis AT rodriguesgeorge phaseiiitrialoffairlybriefandrogensuppressionandstereotacticradiationtherapyforhighriskprostatecancerfastr2preliminaryresultsandtoxicityanalysis |